Evidence map›Paper›PMID 32194171›Full record

ArticleJournal of controlled release : official journal of the Controlled Release Society2020

Renal clearable nanocarriers: Overcoming the physiological barriers for precise drug delivery and clearance.

Chuanqi Peng, Yingyu Huang, Jie Zheng

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of controlled release : official journal of the Controlled Release Society, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Spatiotemporal cancer controlNanomedicine (London, England) · 2026
    Review
  8. Article
  9. Effects of micro and nano plastics on renal health.World journal of nephrology · 2026
    Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Chuanqi PengDepartment of Chemistry and Biochemistry, The University of Texas at Dallas, 800 West Campbell Road, Richardson, TX 75080, USA.
Yingyu HuangDepartment of Chemistry and Biochemistry, The University of Texas at Dallas, 800 West Campbell Road, Richardson, TX 75080, USA.
Jie ZhengDepartment of Chemistry and Biochemistry, The University of Texas at Dallas, 800 West Campbell Road, Richardson, TX 75080, USA. Electronic address: jiezheng@utdallas.edu.

Funding

Glomerular Filtration of Sub-nm Gold NanoparticlesR01DK115986 · NIDDK · UNIVERSITY OF TEXAS DALLAS · PI ZHENG, JIE · 2018 to 2021
$1.4M
Surface chemistry for high-contrast fluorescence kidney imagingR01DK103363 · NIDDK · UNIVERSITY OF TEXAS DALLAS · PI ZHENG, JIE · 2014 to 2018
$1.3M
NIDDK NIH HHS R01 DK103363NIDDK NIH HHS R01 DK115986
6 · The paper itself

Abstract

Physiological barriers encountered in the clinical translation of cancer nanomedicines inspire the community to more deeply understand nano-bio interactions in not only tumor microenvironment but also entire body and develop new nanocarriers to tackle these barriers. Renal clearable nanocarriers are one kind of these newly emerged drug delivery systems (DDSs), which enable drugs to rapidly penetrate into the tumor cores with no need of long blood retention and escape macrophage uptake in the meantime they can also enhance body elimination of non-targeted anticancer drugs. As a result, they can improve therapeutic efficacies and reduce side effects of anticancer drugs. Not limited to anticancer drugs, diagnostic agents can also be achieved with these renal clearable DDSs, which might also be applied to improve the precision in the gene editing and immunotherapy in the future.

Indexed as

Antineoplastic AgentsNanoparticlesNeoplasmsPharmaceutical PreparationsDrug CarriersDrug Delivery SystemsHumansNanomedicineTumor MicroenvironmentAntineoplastic AgentsDrug CarriersPharmaceutical PreparationsCancerDrug deliveryNanocarriersNanomedicineNanoparticlePhysiological barriersRenal clearance

Identifiers

PMID32194171
PMCPMC8696951

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.